Current Report Filing (8-k)
January 27 2022 - 02:05PM
Edgar (US Regulatory)
0001348362false00013483622022-01-272022-01-27iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of
1934
|
Date of Report (Date of earliest event reported)
|
January 27,
2022
|
|
LEXARIA BIOSCIENCE
CORP.
|
|
(Exact name of registrant as specified in its charter)
|
|
Nevada
|
|
000-52138
|
|
20-2000871
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
100 – 740 McCurdy Road, Kelowna, BC Canada
|
|
V1X 2P7
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code (250)
765-6424
______________________________________
(Former name or former address, if changed since last
report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
Common Stock, par value $0.001 per share
Warrants to Purchase Common Stock
|
|
LEXX
LEXXW
|
|
The Nasdaq Capital Market
The Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
|
Item 7.01
|
Regulation FD Disclosure
|
Christopher Bunka, the Chief Executive Officer of Lexaria
Bioscience Corp. (“Lexaria”) has issued a letter discussing
Lexaria’s strategic outlook and summarizing its accomplishments
during the 2021 year. A copy of the letter is attached as
Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the
information in this Current Report on Form 8-K, including Exhibit
99.1, shall not be deemed “filed” for the purposes of Section 18 of
the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that section. The information in this
Current Report on Form 8-K shall not be incorporated by reference
into any filing or other document pursuant to the Securities Act of
1933, as amended, except as shall be expressly set forth by
specific reference in such filing or document.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
LEXARIA BIOSCIENCE CORP.
|
|
|
|
|
|
/s/ Chris Bunka
|
|
|
Chris Bunka
|
|
|
CEO, Principal Executive Officer
|
|
|
|
|
|
Date:
|
January 27, 2022
|
|
Lexaria Bioscience (NASDAQ:LEXX)
Historical Stock Chart
From Apr 2022 to May 2022
Lexaria Bioscience (NASDAQ:LEXX)
Historical Stock Chart
From May 2021 to May 2022
